Webinar: COVID-19 and Alcohol-associated Liver Disease

When:  Dec 10, 2020 from 5:00 PM to 6:00 PM (ET)

Content Contributors

  • American Association for the Study of Liver Diseases
  • AASLD COVID-19 Clinical Oversight Subcommittee
  • AASLD Alcohol-associated Liver Disease SIG


  • Brenda Curtis, PhD, MsPH
    NIH / National Institute on Drug Abuse
  • Andrew Moon, MD, MPH
    University of North Carolina, Division of Gastroenterology and Hepatology


  • Pranoti Mandrekar, PhD, FAASLD
    University of Massachusetts Medical School
  • Ashwani K. Singal, MD, MS, FACG, FAASLD
    University of South Dakota


  • Elizabeth C. Verna, MD, MS
    Columbia University Medical Center


Alcohol-associated liver disease (ALD) is the leading etiology for end-stage liver disease, acute-on-chronic liver failure, and need for liver transplantation. Alcohol use is the most important modifiable risk factor for ALD.

Since February-March 2020, Covid-19 pandemic has altered lifestyle across the world including the US, which includes healthcare. Apart from general effects of COVID-19 pandemic on care of ALD patients, social distancing and many other factors have impacted patient behavior including alcohol consumption.

Attendees of this webinar will:

  • Recognize the impact of COVID-19 on alcohol consumption and alcohol use disorder (AUD)
  • Learn the impact of COVID-19 on the frequency and severity of ALD in both pre- and post-transplant settings.